Nefroangioesclerosis

  1. Quiroga, B.
  2. Arroyo, D.
  3. de la Fuente, G. de Arriba
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2019

Título del ejemplar: Enfermedades nefrourinarias (III) Hipertensión y enfermedades vasculares renales

Serie: 12

Número: 81

Páginas: 4765-4771

Tipo: Artículo

DOI: 10.1016/J.MED.2019.06.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Nephroangiosclerosis is a disorder commonly related with chronic and poorly controlled hypertension; its changes are very similar to those produced by aging. It shows an unspecific clinical picture characterized by mild-moderate renal failure with proteinuria less than 1 gram. It takes place years after the diagnosis of arterial blood hypertension and rarely progresses to end-stage chronic renal failure. It can be related to other cardiovascular risk factors. Patients frequently show a clinical history of ischemic event, for example acute myocardial infarction and stroke. Nephrosclerosis is a diagnosis of exclusion and biopsy rarely is done. Treatment relies on arterial pressure control by the use of renin-angiotensin-aldosterone blockers, as well as the management of the other cardiovascular risk factors.

Referencias bibliográficas

  • Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP. Effect of ramipril vs amlodipine on renal outcomes in hypertensivenephrosclerosis: a randomized controlled trial. JAMA. 2001;285: 2719-28.
  • Békássy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D. Aliskireninhibits renin mediated complement activation. Kidney Int. 2018;94:689-700.
  • Bohle A, Wehrmann M, Greschniok A, Junghans R. Renal morphology in essential hypertension: analysis of 1177 unselected cases. Kidney Int Suppl. 1998;67:S205-6.
  • Cooper Worobey C, Fisher ND, Cox D, Forman JP, Curhan GC. Genetic polymorphisms and the risk of accelerated renal function decline in women. PLoS One. 2009;4:e4787.
  • Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997;51:244-52.
  • Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovasc Drugs Ther. 2018;32: 255-63.
  • Goicoechea M, García de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A. Allopurinol and progression of CKD and cardiovascular events: long term follow up of a randomized clinical trial. Am J Kidney Dis. 2015; 65:543-9.
  • Hernando Avendaño L. Nefrología clínica. 3ª ed. Madrid: Editorial Panamericana; 2009.
  • Iseki K, Ikemiya Y, Fukiyama K. Blood pressure and risk of end stage renal disease in a screened cohort. Kidney Int Suppl. 1996;55:S69-S71.
  • Jürgen Floege RJJ, John Feehally. Comprehensive clinical nephrology. 4º ed. St. Louis: Elsevier, Saunders; 2010.
  • Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334: 13-8.
  • Liang S, Le W, Liang D, Chen H, Xu F, Chen H. Clinicopathological characteristics and outcomes of patients with biopsy proven hypertensive nephrosclerosis: a retrospective cohort study. BMC Nephrol. 2016;17:42.
  • Liang S, Le W, Liang D, Chen H, Xu F, Chen H. Clinicopathological characteristics and outcomes of patients with biopsy proven hypertensive nephrosclerosis: a retrospective cohort study. BMC Nephrol. 2016;17:42.
  • Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH. Apolipoprotein L1 genevariants associate with hypertension attributed nephropathy and the rate ofkidney function decline in African Americans. Kidney Int. 2013;83:114-20.
  • Lusco MA, Najafian B, Alpers CE, Fogo AB. AJKD atlas of renal pathology: arterionephrosclerosis. Am J Kidney Dis. 2016;67:e21-2.
  • Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-200.
  • McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin angiotensin system activation and ambulatory BP: a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12:807-16.
  • Meyrier A. Nephrosclerosis: update on a centenarian. Nephrol Dial Transplant. 2015;30:1833-41.
  • Meyrier A. Nephrosclerosis: a term in quest of a disease. Nephron. 2015; 129:276-82.
  • Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G. Hypertensionawareness, treatment, and control in adults with CKD: results from the ChronicRenal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441-51.
  • Nansseu JR, Noubiap JJ. Aspirin for primary prevention of cardiovascular disease. Thromb J. 2015;13:38.
  • O’Sullivan ED, Hughes J, Ferenbach DA. Renal aging: causes and consequences. J Am Soc Nephrol. 2017;28:407-20
  • Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369:2183-96.
  • Quiroga B, Fernández Juárez G, Luño J. Combined angiotensin inhibition in diabetic nephropathy. N Engl J Med. 2014;370:777.
  • Raju N, Sobieraj-Teague M, Bosch J, Eikelboom JW. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med. 2016;129:e35-6.
  • Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES),1999-2004. Am J Kidney Dis. 2008; 51(4)Suppl2:S30-7.
  • Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis. 1994;23(5): 655-60.
  • Seccia TM, Caroccia B, Calò LA. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35:205-12.
  • Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303-9.
  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C. Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324.
  • Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M. Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953-2041.
  • Yamanouchi M, Hoshino J, Ubara Y, Takaichi K, Kinowaki K, Fujii T. Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy based cohort study. Nephrol Dial Transplant. 2018 [Internet].
  • Yu XJ, Yu F, Song D, Wang SX, Song Y, Liu G. Clinical and renal biopsy findings predicting outcome in renal thrombotic microangiopathy: a large cohort study from a single institute in China. Scientific World Journal. 2014;2014:680502.
  • Zucchelli P, Zuccalà A. Can we accurately diagnose nephrosclerosis? Nephrol Dial Transplant. 1995;10 Suppl 6:2-5.
Fuente de los datos: Dialnet